You are here

Article Text

Article menu
Download PDFPDF
Letters
Mycophenolate mofetil for lupus related myelopathy
  1. C C Mok,
  2. A Mak,
  3. C H To
  1. Department of Medicine, Tuen Mun Hospital, Hong Kong SAR, China
  1. Correspondence to:
    Dr C C Mok
    ccmok2005{at}yahoo.com

https://doi.org/10.1136/ard.2005.046615

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Myelopathy is a rare manifestation of systemic lupus erythematosus (SLE). The standard treatment consists of high dose corticosteroids and intravenous pulse cyclophosphamide (CYC).1,2 Despite this, our previous experience indicated that half of the patients with lupus related myelopathy did not respond completely to CYC treatment.3 Moreover, toxicities of CYC are of major concern, particularly severe infections and ovarian failure.4 Therefore, less toxic or more effective alternative treatments are needed.

    Mycophenolate mofetil (MMF) is a relatively new immunosuppressive agent that has increasingly been used in patients with SLE because of its favourable efficacy and safety.5 Controlled trials have confirmed its efficacy in …

    View Full Text